|

Elotuzumab Clinical Trials

6 actively recruiting trials across 6 locations

▼ -1 trial since August 2026

Also known as: BMS 901608, BMS-901608, BMS901608, Empliciti, Empliciti® +5 more

Pipeline

Phase 3: 3Phase 1/2: 3

Top Sponsors

  • Regeneron Pharmaceuticals1
  • Pfizer1
  • Omar Nadeem, MD1
  • Mayo Clinic1
  • Karyopharm Therapeutics Inc1

Indications

  • Cancer6
  • Multiple Myeloma4
  • Relapsed Refractory Multiple Myeloma (RRMM)1
  • Recurrent Multiple Myeloma1
  • Myeloma1

Mobile, Alabama1 trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Infirmary Cancer Care

Phase 3

Gilbert, Arizona1 trial

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Duarte, California1 trial

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

City of Hope National Medical Center

Phase 3

Los Angeles, California1 trial

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

University of California Los Angeles (UCLA)

Phase 3

Boston, Massachusetts1 trial

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Brigham and Women's Hospital

Phase 1/2

Rochester, Minnesota1 trial

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Mayo Clinic in Rochester

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.